- Home
- BHRB vs GERN Comparison
BHRB vs GERN Comparison
Compare BHRB & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHRB
- GERN
- Stock Information
- Founded
- BHRB 1852
- GERN 1990
- Country
- BHRB United States
- GERN United States
- Employees
- BHRB N/A
- GERN N/A
- Industry
- BHRB Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- BHRB Finance
- GERN Health Care
- Exchange
- BHRB Nasdaq
- GERN Nasdaq
- Market Cap
- BHRB 843.3M
- GERN 853.5M
- IPO Year
- BHRB N/A
- GERN 1996
- Fundamental
- Price
- BHRB $56.56
- GERN $1.44
- Analyst Decision
- BHRB Strong Buy
- GERN Buy
- Analyst Count
- BHRB 2
- GERN 9
- Target Price
- BHRB $73.00
- GERN $5.13
- AVG Volume (30 Days)
- BHRB 31.1K
- GERN 13.0M
- Earning Date
- BHRB 07-25-2025
- GERN 05-07-2025
- Dividend Yield
- BHRB 3.87%
- GERN N/A
- EPS Growth
- BHRB 46.75
- GERN N/A
- EPS
- BHRB 3.98
- GERN N/A
- Revenue
- BHRB $288,679,000.00
- GERN $116,293,000.00
- Revenue This Year
- BHRB $51.95
- GERN $160.12
- Revenue Next Year
- BHRB $4.56
- GERN $55.01
- P/E Ratio
- BHRB $14.31
- GERN N/A
- Revenue Growth
- BHRB 168.50
- GERN 22264.04
- 52 Week Low
- BHRB $46.00
- GERN $1.17
- 52 Week High
- BHRB $75.32
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- BHRB 53.55
- GERN 54.80
- Support Level
- BHRB $56.15
- GERN $1.40
- Resistance Level
- BHRB $57.31
- GERN $1.60
- Average True Range (ATR)
- BHRB 1.38
- GERN 0.11
- MACD
- BHRB -0.13
- GERN 0.03
- Stochastic Oscillator
- BHRB 47.74
- GERN 69.64
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.